类别 for 新型冠状病毒肺炎 /冠状病毒

Lonza and Moderna Announce Further Collaboration For Drug Substance 制造业 of 新型冠状病毒肺炎 Vaccine Moderna in the Netherlands

Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The expanded collaboration will further extend the manufacture of the drug substance for the 新型冠状病毒肺炎 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.

2021年6月2日

Best Practices and Considerations for Developing Vaccine 政策 in the 专业 Chemical Industry

As SOCMA continues to keep a pulse on the specialty and fine chemical industry, we understand that companies across the industry are grappling with how to encourage employee inoculations now that there’s increased availability of 新型冠状病毒肺炎 vaccines. We’ve spoken with leaders from Texas to Rhode Island and everywhere in between about how they are handling the vaccination within their companies, and here are a few takeaways you can consider when implementing your own plans.

2021年3月22日

SOCMA政策博客

SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, 健康与安全委员会. 与真钱地址下载的会员, we are prepared to further our advocacy efforts through each agency's review and decision process.

2021年1月27日

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Capricor疗法, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from 新型冠状病毒肺炎.

2021年1月12日

Humanigen and Lonza Announce Collaboration to Expand 制造业 of Humanigen’s 新型冠状病毒肺炎 Therapeutic Candidate Lenzilumab

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for 新型冠状病毒肺炎, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.

2020年9月16日